Skip to main content

Table 1 Comparison of cardiology evaluation and cardiovascular imaging modalities in patients before/during treatment versus during survivorship care, by provider report. Patients were more likely to be evaluated by a cardiologist post-treatment or during survivorship care than prior/during cancer treatment. There was an increase in use of Cardiac MR imaging as part of survivorship care

From: The landscape of cardiovascular care in pediatric cancer patients and survivors: a survey by the ACC Pediatric Cardio-Oncology Work Group

Cardiac Visit/Cardiac Testing Before/During Treatment
(N = 64)
After Treatment/Survivorship
(N = 65)
P-value
Evaluation by a Cardiologist 8 (12%) 28 (43%) < 0.01
Electrocardiogram 48 (75%) 43 (66%) 0.27
Extended arrhythmia monitoring 2 (3%) 7 (11%) 0.16
Echocardiogram, standarda 37 (58%) 36 (55%) 0.77
Echocardiogram, advancedb 32 (50%) 35 (54%) 0.66
Cardiac magnetic resonance imaging 2 (3%) 11 (17%) < 0.01
Radionuclide imaging (e.g. MUGA) 0 (0%) 2 (3%) 0.50
Serum biomarkers 5 (8%) n/a
Cardiopulmonary exercise testing n/a 5 (8%)
None 0 (0%) 0 (0%) 1.00
Other/Unknown/not applicable 9 (14%) 8 (12%) 0.76
  1. MUGA Multi-gated acquisition scan, n/a Answer was not an option for this question
  2. aIncluding shortening fraction and/or ejection fraction; bincluding diastolic parameters, strain imaging, and stress echocardiography